Gastrointestinal Carcinoma with Plasmacytoid Morphology: Positivity for c-MET, Arylsulfatase, and Markers of Epithelial-Mesenchymal Transition, as Indicators of Aggressivity

Table 4

The immunoprofile of primary carcinoma with plasmacytoid morphology versus metastatic tumors in the gastrointestinal tract (adapted upon 1, 2, 3, 5, 7, 12-16).

BIOMARKER	Gastric PC	Colorectal PC	Urothelial PC	Invasive lobular carcinoma of the breast
CD138	100% positivity	100% positivity	~78% positivity	~90% positivity in metastatic cases, in epithelium and/or stroma
CK AE1/AE3	97% positivity	100% positivity	~97% positivity	Usually positive
CK7	Usually positive	Sporadic positive	~77.4% positivity	Usually positive
CK20	Negative or focally positive	~97% positivity	~72% focal positivity	Usually negative
CDX2	Usually negative	Usually positive	~18% positivity	Negative
CEA	Usually negative	Positive	~49% positivity	Negative
Uroplakin II	Negative	Negative	~33% positivity	Negative
ER	Usually negative	Usually negative	Negative	~95% positivity
PR	Negative	Negative	~13% positivity	~76-83% positivity
Mammaglobin	Negative	Negative	Negative	Usually positive
GCPDFP-15	Negative	Negative	~24% positivity	Usually negative
GATA 3	Negative or weak and sporadic	Negative	~70-88% positivity	≥90% positivity (only 22% in triple negative tumors)
MLH-1	Usually positive, usually MSS	Usually positive, usually MSS	No data in PubMed cited papers	Usually positive, usually MSS
MSH-2	Usually positive	Usually positive	No data in PubMed cited papers	Usually positive
PMS-2	Usually positive	Usually positive	No data in PubMed cited papers	No data in PubMed cited papers
MSH-6	Usually positive	Usually positive	No data in PubMed cited papers	No data in PubMed cited papers
E-cadherin	Usually negative	Usually negative	~25% positivity, 75% diminished or negative	~10-25% membrane or aberrant nuclear positivity
β-catenin	Negative or membrane positivity	Nuclear positivity	22.5% negative, 17% nuclear positivity, 60.5% membrane positivity	~90% reduction or complete loss of positivity, 8-10% membrane or cytoplasmic positivity
Vimentin	Usually positive	Negative	Usually negative	~14% positivity
N-cadherin	Usually negative	Usually negative	No data in PubMed cited papers	~4% positivity
VSIG1	Usually positive	Usually positive	No data in PubMed cited papers	Usually negative
SLUG	Usually positive	Usually positive	No data in PubMed cited papers	~2-4% positivity
CD44	Positive or negative	Positive or negative	No data in PubMed cited papers	Positive in metastatic or multidrug resistant cases
Maspin	Negative	Negative or nuclear positivity	No data in PubMed cited papers	~7% cytoplasmic positivity
S100	Negative	Negative	Negative	~57% positivity
VEGF-A	Negative	Negative	No data in PubMed cited papers	Negative or positive
HER-2	Negative	Negative		Usually negative
c-MET	Usually positive	Usually positive	No data in PubMed cited papers	Positive in triple negative metastatic cases